---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-023932"
form_type: "8-K"
ticker: "SIGY"
cik: "0001642159"
company_name: "Sigyn Therapeutics, Inc."
filed_at: "2023-07-07T23:59:59+00:00"
generated_at: "2026-06-13T11:04:37.526203+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sigyn Therapeutics exchanges warrants for common stock and Series A Preferred at $0.199/share

## Summary
- Entered Warrant Exchange Agreements with holders of warrants issued Oct 2020–Feb 2023.
- Exchange ratio: 1 share of common stock for 2 warrants; certain holders receive Series A Preferred to cap beneficial ownership.
- Series A Preferred converts to common at $0.199 per share, has same dividend/liquidation rights as common, no voting rights.
- Preferred Stock issued to accredited investors in private placement exempt from registration under Section 4(a)(2).
- Certificate of Designation for Series A Preferred filed with Delaware; no redemption rights, anti-dilution adjustments apply.

## SEC filing metadata
- accession: 0001493152-23-023932
- form_type: 8-K
- ticker: SIGY
- cik: 0001642159
- company_name: Sigyn Therapeutics, Inc.
- filed_at: 2023-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642159/000149315223023932/0001493152-23-023932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642159/000149315223023932/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-023932
- JSON: https://secwatch.observer/filing/0001493152-23-023932.json
- Plain text: https://secwatch.observer/filing/0001493152-23-023932.txt

## Key facts
- Governance Changes
  Sigyn Therapeutics, Inc.: Filed a certificate of designation establishing the rights, preferences, privileges and restrictions of a series of Preferred Stock (effective 2023-06-30).
  - Change: charter amendment
  - Effective: 2023-06-30
  source text: On June 30, 2023, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the shares of Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642159/000149315223023932/0001493152-23-023932-index.htm
- Material Agreements
  Sigyn Therapeutics, Inc. entered into Warrant Exchange Agreements with certain holders of warrants issued between October 20, 2020 and February 9, 2023 (effective 2023-06-30).
  - Action: entry
  - Counterparty: certain holders of warrants issued between October 20, 2020 and February 9, 2023
  - Effective: 2023-06-30
  source text: On June 30, 2023, Sigyn Therapeutics, Inc. (the “Company”) entered into Warrant Exchange Agreements with certain holders of warrants issued between October 20, 2020 and February 9, 2023 (the “Warrants”) to exchange the Warrants for newly issued shares of Common Stock and Series A Preferred Stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642159/000149315223023932/0001493152-23-023932-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.